RAPT - NASDAQ
RAPT Therapeutics, Inc.
$58.01
+0.0000%RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotRAPT Therapeutics, Inc. Management Team
Dr. Brian Russell Wong M.D., Ph.D.
Chief Executive Officer, President & Director
Compensation
$1,052,242
Mr. Rodney K. B. Young
Chief Financial Officer, Principal Accounting Officer & Secretary
Compensation
$716,004
Ms. Gwen R. Carscadden
Chief Human Resources Officer
Dr. William Ho M.D., Ph.D.
Chief Medical Officer
Compensation
$709,582
Dr. Dirk G. Brockstedt Ph.D.
Chief Scientific Officer
Compensation
$490,250
Mr. Michael Listgarten
General Counsel
Dr. Paul Kassner Ph.D.
Senior Vice President of Biology
Ms. Jennifer Nicholson
Senior Vice President of Regulatory Affairs & Quality Assurance
Dr. Nipun Davar MBA, Ph.D.
Senior Vice President of Technical Operations
Steve Young Ph.D.
Vice President of Technology
RAPT Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $186K worth of RAPT shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
25.0K
185.75K
0
0.00
+186K
+$186K
Top Buyers
Dombkowski Ashley L.
Director
$186K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $186K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
SEC Filings
RAPT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 14, 2025 | May 29, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 05, 2024 | May 22, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 07, 2023 | May 24, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 11, 2022 | May 25, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 15, 2021 | May 28, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 18, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.